Literature DB >> 16163519

Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice.

Brooke N Bourdélat-Parks1, George M Anderson, Zoe R Donaldson, Jay M Weiss, Robert W Bonsall, Milburn S Emery, L Cameron Liles, David Weinshenker.   

Abstract

RATIONALE: Dopamine beta-hydroxylase (DBH) converts dopamine (DA) to norepinephrine (NE), thus playing a critical role in catecholamine metabolism. OBJECTIVES/
METHODS: We examined the effects of Dbh gene dosage and the DBH inhibitor disulfiram in mice with zero, one, or two null Dbh alleles (+/+, +/-, and-/- mice).
RESULTS: DBH protein levels in adrenal and prefrontal cortex (PFC) and adrenal DBH activity were proportional to number of wild-type alleles. Adrenal DA was slightly increased in+/- mice and markedly increased (80-fold) in -/- mice compared to wild-type animals. While adrenal NE and epinephrine (EPI) were undetectable in -/- mice, adrenal concentrations of NE and EPI were similar in +/+ and +/- mice, suggesting that the increase in DA maintains the normal rate of beta-hydroxylation in Dbh +/- mice. Disulfiram had little effect on adrenal catecholamine levels, regardless of genotype or dose. NE was absent in the PFC of -/- mice, but only slightly reduced in +/- animals compared to wild-type animals. PFC DA was increased twofold in +/- mice and fivefold in -/- mice, and the NE to DA ratio was reduced ( approximately 35%) in +/- mice, compared to wild-type mice. Disulfiram significantly decreased PFC NE and increased DA in +/+ and +/- animals, with the disulfiram and genotype effects on the PFC NE to DA ratio apparently additive.
CONCLUSIONS: The data reveal potentially important and apparently additive effects of Dbh genotype and disulfiram administration on PFC catecholamine metabolism. These effects may have implications for genetic control of DBH activity in humans and for understanding therapeutic effects of disulfiram.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16163519     DOI: 10.1007/s00213-005-0139-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  39 in total

1.  INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY DISULFIRAM.

Authors:  M GOLDSTEIN; B ANAGNOSTE; E LAUBER; M R MCKEREGHAM
Journal:  Life Sci (1962)       Date:  1964-07

2.  Norepinephrine-dopamine interactions in the prefrontal cortex and the ventral tegmental area: relevance to mental diseases.

Authors:  J P Tassin
Journal:  Adv Pharmacol       Date:  1998

3.  Inhibition of norepinephrine biosynthesis at the dopamine-beta-hydroxylation stage.

Authors:  M Goldstein
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

4.  Chronic disulfiram treatment effects on intranasal cocaine administration: initial results.

Authors:  E F McCance-Katz; T R Kosten; P Jatlow
Journal:  Biol Psychiatry       Date:  1998-04-01       Impact factor: 13.382

5.  Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial.

Authors:  T P George; M C Chawarski; J Pakes; K M Carroll; T R Kosten; R S Schottenfeld
Journal:  Biol Psychiatry       Date:  2000-06-15       Impact factor: 13.382

6.  A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus.

Authors:  C P Zabetian; G M Anderson; S G Buxbaum; R C Elston; H Ichinose; T Nagatsu; K S Kim; C H Kim; R T Malison; J Gelernter; J F Cubells
Journal:  Am J Hum Genet       Date:  2001-01-19       Impact factor: 11.025

Review 7.  Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology.

Authors:  J F Cubells; C P Zabetian
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

8.  Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases.

Authors:  D J Stewart; T Inaba; M Lucassen; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1979-04       Impact factor: 6.875

9.  Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.

Authors:  Kathleen M Carroll; Lisa R Fenton; Samuel A Ball; Charla Nich; Tami L Frankforter; Julia Shi; Bruce J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2004-03

10.  BEHAVIORAL AND METABOLIC CHANGES ASSOCIATED WITH ADMINISTRATION OF TETRAETHYLTHIURAM DISULFIDE (ANTABUSE).

Authors:  R G HEATH; W NESSELHOF; M P BISHOP; L W BYERS
Journal:  Dis Nerv Syst       Date:  1965-02
View more
  44 in total

Review 1.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

2.  Cocaine sobers up.

Authors:  David Weinshenker
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

Review 3.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

4.  Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels.

Authors:  Patricia Di Ciano; Daniel F Manvich; Abhiram Pushparaj; Andrew Gappasov; Ellen J Hess; David Weinshenker; Bernard Le Foll
Journal:  Psychopharmacology (Berl)       Date:  2017-10-30       Impact factor: 4.530

Review 5.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

Review 6.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

7.  Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease.

Authors:  Maja Mustapic; Paola Presecki; Nela Pivac; Ninoslav Mimica; Patrick R Hof; Goran Simic; Vera Folnegovic-Smalc; Dorotea Muck-Seler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-02-13       Impact factor: 5.067

8.  Chronic loss of noradrenergic tone produces β-arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens.

Authors:  Meriem Gaval-Cruz; Richard B Goertz; Daniel J Puttick; Dawn E Bowles; Rebecca C Meyer; Randy A Hall; Daijin Ko; Carlos A Paladini; David Weinshenker
Journal:  Addict Biol       Date:  2014-08-13       Impact factor: 4.280

9.  Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Authors:  Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.